nodes	percent_of_prediction	percent_of_DWPC	metapath
Pravastatin—CYP3A4—bone cancer	0.279	1	CbGaD
Pravastatin—SLC16A1—Methotrexate—bone cancer	0.0775	0.127	CbGbCtD
Pravastatin—ABCB11—Doxorubicin—bone cancer	0.0435	0.0714	CbGbCtD
Pravastatin—SLCO1B3—Methotrexate—bone cancer	0.0433	0.071	CbGbCtD
Pravastatin—SLC22A11—Methotrexate—bone cancer	0.04	0.0656	CbGbCtD
Pravastatin—ABCC2—Carboplatin—bone cancer	0.0399	0.0655	CbGbCtD
Pravastatin—SLC22A7—Methotrexate—bone cancer	0.0381	0.0625	CbGbCtD
Pravastatin—ABCG2—Carboplatin—bone cancer	0.0361	0.0592	CbGbCtD
Pravastatin—ABCC2—Cisplatin—bone cancer	0.0341	0.056	CbGbCtD
Pravastatin—ABCG2—Cisplatin—bone cancer	0.0308	0.0506	CbGbCtD
Pravastatin—SLCO1A2—Methotrexate—bone cancer	0.0267	0.0438	CbGbCtD
Pravastatin—SLCO1B1—Methotrexate—bone cancer	0.0252	0.0414	CbGbCtD
Pravastatin—SLC22A8—Methotrexate—bone cancer	0.0233	0.0382	CbGbCtD
Pravastatin—ABCC2—Doxorubicin—bone cancer	0.0229	0.0375	CbGbCtD
Pravastatin—ABCC2—Methotrexate—bone cancer	0.0221	0.0363	CbGbCtD
Pravastatin—ABCG2—Doxorubicin—bone cancer	0.0207	0.0339	CbGbCtD
Pravastatin—ABCG2—Methotrexate—bone cancer	0.02	0.0329	CbGbCtD
Pravastatin—SLC22A6—Methotrexate—bone cancer	0.0162	0.0266	CbGbCtD
Pravastatin—CYP2C9—Cisplatin—bone cancer	0.0115	0.0188	CbGbCtD
Pravastatin—ABCB1—Cisplatin—bone cancer	0.0111	0.0183	CbGbCtD
Pravastatin—ABCB1—Doxorubicin—bone cancer	0.00745	0.0122	CbGbCtD
Pravastatin—ABCB1—Methotrexate—bone cancer	0.00722	0.0118	CbGbCtD
Pravastatin—CYP2D6—Doxorubicin—bone cancer	0.00702	0.0115	CbGbCtD
Pravastatin—CYP3A4—Doxorubicin—bone cancer	0.00447	0.00733	CbGbCtD
Pravastatin—Simvastatin—CYP3A4—bone cancer	0.00123	0.505	CrCbGaD
Pravastatin—Lovastatin—CYP3A4—bone cancer	0.0012	0.495	CrCbGaD
Pravastatin—SLC22A7—Fluoropyrimidine Activity—DHFR—bone cancer	0.000676	0.0158	CbGpPWpGaD
Pravastatin—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000672	0.0157	CbGpPWpGaD
Pravastatin—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000662	0.0154	CbGpPWpGaD
Pravastatin—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.000657	0.0153	CbGpPWpGaD
Pravastatin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000651	0.0152	CbGpPWpGaD
Pravastatin—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00065	0.0152	CbGpPWpGaD
Pravastatin—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000622	0.0145	CbGpPWpGaD
Pravastatin—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000621	0.0145	CbGpPWpGaD
Pravastatin—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000569	0.0133	CbGpPWpGaD
Pravastatin—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000536	0.0125	CbGpPWpGaD
Pravastatin—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000534	0.0124	CbGpPWpGaD
Pravastatin—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000533	0.0124	CbGpPWpGaD
Pravastatin—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000532	0.0124	CbGpPWpGaD
Pravastatin—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000529	0.0123	CbGpPWpGaD
Pravastatin—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000506	0.0118	CbGpPWpGaD
Pravastatin—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.0005	0.0117	CbGpPWpGaD
Pravastatin—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000482	0.0112	CbGpPWpGaD
Pravastatin—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.0004	0.00932	CbGpPWpGaD
Pravastatin—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000399	0.00931	CbGpPWpGaD
Pravastatin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00038	0.00887	CbGpPWpGaD
Pravastatin—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000377	0.0088	CbGpPWpGaD
Pravastatin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000362	0.00845	CbGpPWpGaD
Pravastatin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000349	0.00814	CbGpPWpGaD
Pravastatin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000348	0.00812	CbGpPWpGaD
Pravastatin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000328	0.00766	CbGpPWpGaD
Pravastatin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000323	0.00753	CbGpPWpGaD
Pravastatin—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000314	0.00732	CbGpPWpGaD
Pravastatin—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000311	0.00726	CbGpPWpGaD
Pravastatin—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000308	0.00718	CbGpPWpGaD
Pravastatin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000306	0.00714	CbGpPWpGaD
Pravastatin—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000302	0.00704	CbGpPWpGaD
Pravastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000286	0.00667	CbGpPWpGaD
Pravastatin—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.00028	0.00653	CbGpPWpGaD
Pravastatin—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000258	0.00601	CbGpPWpGaD
Pravastatin—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000255	0.00595	CbGpPWpGaD
Pravastatin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000249	0.0058	CbGpPWpGaD
Pravastatin—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000248	0.00578	CbGpPWpGaD
Pravastatin—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000246	0.00573	CbGpPWpGaD
Pravastatin—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00023	0.00536	CbGpPWpGaD
Pravastatin—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000228	0.00531	CbGpPWpGaD
Pravastatin—Discomfort—Cisplatin—bone cancer	0.00022	0.00331	CcSEcCtD
Pravastatin—Affect lability—Epirubicin—bone cancer	0.000219	0.0033	CcSEcCtD
Pravastatin—Menopausal symptoms—Doxorubicin—bone cancer	0.000218	0.00329	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000215	0.00502	CbGpPWpGaD
Pravastatin—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000214	0.00322	CcSEcCtD
Pravastatin—Purpura—Doxorubicin—bone cancer	0.000214	0.00322	CcSEcCtD
Pravastatin—Oedema—Cisplatin—bone cancer	0.000213	0.00321	CcSEcCtD
Pravastatin—Anaphylactic shock—Cisplatin—bone cancer	0.000213	0.00321	CcSEcCtD
Pravastatin—Infection—Cisplatin—bone cancer	0.000212	0.00319	CcSEcCtD
Pravastatin—Mood swings—Epirubicin—bone cancer	0.000211	0.00317	CcSEcCtD
Pravastatin—Thrombocytopenia—Cisplatin—bone cancer	0.000209	0.00314	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000207	0.00483	CbGpPWpGaD
Pravastatin—Diplopia—Doxorubicin—bone cancer	0.000206	0.0031	CcSEcCtD
Pravastatin—Hyperhidrosis—Cisplatin—bone cancer	0.000206	0.0031	CcSEcCtD
Pravastatin—Liver function test abnormal—Epirubicin—bone cancer	0.000206	0.00309	CcSEcCtD
Pravastatin—Dry skin—Epirubicin—bone cancer	0.000204	0.00307	CcSEcCtD
Pravastatin—Eosinophilia—Methotrexate—bone cancer	0.000204	0.00306	CcSEcCtD
Pravastatin—Anorexia—Cisplatin—bone cancer	0.000203	0.00306	CcSEcCtD
Pravastatin—Affect lability—Doxorubicin—bone cancer	0.000203	0.00305	CcSEcCtD
Pravastatin—Pancreatitis—Methotrexate—bone cancer	0.000202	0.00303	CcSEcCtD
Pravastatin—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.0002	0.00302	CcSEcCtD
Pravastatin—Nasopharyngitis—Epirubicin—bone cancer	0.000199	0.003	CcSEcCtD
Pravastatin—Muscular weakness—Epirubicin—bone cancer	0.000196	0.00296	CcSEcCtD
Pravastatin—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000196	0.00296	CcSEcCtD
Pravastatin—Mood swings—Doxorubicin—bone cancer	0.000195	0.00294	CcSEcCtD
Pravastatin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000194	0.00292	CcSEcCtD
Pravastatin—Abdominal distension—Epirubicin—bone cancer	0.000194	0.00292	CcSEcCtD
Pravastatin—Influenza—Epirubicin—bone cancer	0.000192	0.0029	CcSEcCtD
Pravastatin—Dysuria—Methotrexate—bone cancer	0.000192	0.00289	CcSEcCtD
Pravastatin—Paraesthesia—Cisplatin—bone cancer	0.000191	0.00288	CcSEcCtD
Pravastatin—Upper respiratory tract infection—Methotrexate—bone cancer	0.000191	0.00288	CcSEcCtD
Pravastatin—Eosinophilia—Epirubicin—bone cancer	0.000191	0.00287	CcSEcCtD
Pravastatin—Liver function test abnormal—Doxorubicin—bone cancer	0.00019	0.00286	CcSEcCtD
Pravastatin—Dyspnoea—Cisplatin—bone cancer	0.00019	0.00286	CcSEcCtD
Pravastatin—Erectile dysfunction—Methotrexate—bone cancer	0.000189	0.00285	CcSEcCtD
Pravastatin—Dry skin—Doxorubicin—bone cancer	0.000189	0.00284	CcSEcCtD
Pravastatin—Pancreatitis—Epirubicin—bone cancer	0.000189	0.00284	CcSEcCtD
Pravastatin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000189	0.0044	CbGpPWpGaD
Pravastatin—Photosensitivity reaction—Methotrexate—bone cancer	0.000188	0.00283	CcSEcCtD
Pravastatin—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000188	0.00438	CbGpPWpGaD
Pravastatin—Angina pectoris—Epirubicin—bone cancer	0.000187	0.00282	CcSEcCtD
Pravastatin—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000185	0.00279	CcSEcCtD
Pravastatin—Decreased appetite—Cisplatin—bone cancer	0.000185	0.00279	CcSEcCtD
Pravastatin—Nasopharyngitis—Doxorubicin—bone cancer	0.000184	0.00277	CcSEcCtD
Pravastatin—Depression—Methotrexate—bone cancer	0.000183	0.00275	CcSEcCtD
Pravastatin—Pain—Cisplatin—bone cancer	0.000182	0.00274	CcSEcCtD
Pravastatin—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000182	0.00274	CcSEcCtD
Pravastatin—Muscular weakness—Doxorubicin—bone cancer	0.000182	0.00274	CcSEcCtD
Pravastatin—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000182	0.00274	CcSEcCtD
Pravastatin—Dysuria—Epirubicin—bone cancer	0.00018	0.00271	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00018	0.00419	CbGpPWpGaD
Pravastatin—Abdominal distension—Doxorubicin—bone cancer	0.000179	0.0027	CcSEcCtD
Pravastatin—Upper respiratory tract infection—Epirubicin—bone cancer	0.000179	0.00269	CcSEcCtD
Pravastatin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000179	0.00417	CbGpPWpGaD
Pravastatin—Influenza—Doxorubicin—bone cancer	0.000178	0.00268	CcSEcCtD
Pravastatin—Eosinophilia—Doxorubicin—bone cancer	0.000176	0.00265	CcSEcCtD
Pravastatin—Photosensitivity reaction—Epirubicin—bone cancer	0.000176	0.00264	CcSEcCtD
Pravastatin—Feeling abnormal—Cisplatin—bone cancer	0.000176	0.00264	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000175	0.00409	CbGpPWpGaD
Pravastatin—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000175	0.00409	CbGpPWpGaD
Pravastatin—Weight increased—Epirubicin—bone cancer	0.000175	0.00264	CcSEcCtD
Pravastatin—Pancreatitis—Doxorubicin—bone cancer	0.000175	0.00263	CcSEcCtD
Pravastatin—Weight decreased—Epirubicin—bone cancer	0.000174	0.00262	CcSEcCtD
Pravastatin—Angina pectoris—Doxorubicin—bone cancer	0.000173	0.00261	CcSEcCtD
Pravastatin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00017	0.00256	CcSEcCtD
Pravastatin—Body temperature increased—Cisplatin—bone cancer	0.000168	0.00254	CcSEcCtD
Pravastatin—Neuropathy peripheral—Epirubicin—bone cancer	0.000168	0.00253	CcSEcCtD
Pravastatin—Jaundice—Epirubicin—bone cancer	0.000167	0.00252	CcSEcCtD
Pravastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000167	0.0039	CbGpPWpGaD
Pravastatin—Urinary tract infection—Epirubicin—bone cancer	0.000167	0.00251	CcSEcCtD
Pravastatin—Dysuria—Doxorubicin—bone cancer	0.000166	0.00251	CcSEcCtD
Pravastatin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000165	0.00249	CcSEcCtD
Pravastatin—Hepatitis—Methotrexate—bone cancer	0.000165	0.00248	CcSEcCtD
Pravastatin—Pharyngitis—Methotrexate—bone cancer	0.000163	0.00246	CcSEcCtD
Pravastatin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000162	0.00245	CcSEcCtD
Pravastatin—Weight increased—Doxorubicin—bone cancer	0.000162	0.00244	CcSEcCtD
Pravastatin—Weight decreased—Doxorubicin—bone cancer	0.000161	0.00242	CcSEcCtD
Pravastatin—Sinusitis—Epirubicin—bone cancer	0.000161	0.00242	CcSEcCtD
Pravastatin—Visual impairment—Methotrexate—bone cancer	0.000159	0.00239	CcSEcCtD
Pravastatin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000157	0.00237	CcSEcCtD
Pravastatin—Hypersensitivity—Cisplatin—bone cancer	0.000157	0.00236	CcSEcCtD
Pravastatin—Erythema multiforme—Methotrexate—bone cancer	0.000156	0.00234	CcSEcCtD
Pravastatin—Neuropathy peripheral—Doxorubicin—bone cancer	0.000156	0.00234	CcSEcCtD
Pravastatin—Jaundice—Doxorubicin—bone cancer	0.000155	0.00233	CcSEcCtD
Pravastatin—Rhinitis—Epirubicin—bone cancer	0.000154	0.00232	CcSEcCtD
Pravastatin—Urinary tract infection—Doxorubicin—bone cancer	0.000154	0.00232	CcSEcCtD
Pravastatin—Hepatitis—Epirubicin—bone cancer	0.000154	0.00232	CcSEcCtD
Pravastatin—Tinnitus—Methotrexate—bone cancer	0.000153	0.00231	CcSEcCtD
Pravastatin—Hypoaesthesia—Epirubicin—bone cancer	0.000153	0.00231	CcSEcCtD
Pravastatin—Asthenia—Cisplatin—bone cancer	0.000153	0.0023	CcSEcCtD
Pravastatin—Pharyngitis—Epirubicin—bone cancer	0.000153	0.0023	CcSEcCtD
Pravastatin—Cardiac disorder—Methotrexate—bone cancer	0.000153	0.0023	CcSEcCtD
Pravastatin—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000151	0.00352	CbGpPWpGaD
Pravastatin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00015	0.00351	CbGpPWpGaD
Pravastatin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00015	0.0035	CbGpPWpGaD
Pravastatin—Sinusitis—Doxorubicin—bone cancer	0.000149	0.00224	CcSEcCtD
Pravastatin—Visual impairment—Epirubicin—bone cancer	0.000148	0.00223	CcSEcCtD
Pravastatin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000148	0.00346	CbGpPWpGaD
Pravastatin—Chills—Methotrexate—bone cancer	0.000148	0.00222	CcSEcCtD
Pravastatin—Diarrhoea—Cisplatin—bone cancer	0.000146	0.00219	CcSEcCtD
Pravastatin—Erythema multiforme—Epirubicin—bone cancer	0.000146	0.00219	CcSEcCtD
Pravastatin—Alopecia—Methotrexate—bone cancer	0.000145	0.00219	CcSEcCtD
Pravastatin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000144	0.00336	CbGpPWpGaD
Pravastatin—Tinnitus—Epirubicin—bone cancer	0.000144	0.00216	CcSEcCtD
Pravastatin—Flushing—Epirubicin—bone cancer	0.000143	0.00215	CcSEcCtD
Pravastatin—Cardiac disorder—Epirubicin—bone cancer	0.000143	0.00215	CcSEcCtD
Pravastatin—Rhinitis—Doxorubicin—bone cancer	0.000143	0.00215	CcSEcCtD
Pravastatin—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000143	0.00333	CbGpPWpGaD
Pravastatin—Hepatitis—Doxorubicin—bone cancer	0.000142	0.00215	CcSEcCtD
Pravastatin—Hypoaesthesia—Doxorubicin—bone cancer	0.000142	0.00213	CcSEcCtD
Pravastatin—Pharyngitis—Doxorubicin—bone cancer	0.000141	0.00213	CcSEcCtD
Pravastatin—Dysgeusia—Methotrexate—bone cancer	0.00014	0.00211	CcSEcCtD
Pravastatin—Chills—Epirubicin—bone cancer	0.000138	0.00208	CcSEcCtD
Pravastatin—Arrhythmia—Epirubicin—bone cancer	0.000138	0.00207	CcSEcCtD
Pravastatin—Visual impairment—Doxorubicin—bone cancer	0.000137	0.00207	CcSEcCtD
Pravastatin—Alopecia—Epirubicin—bone cancer	0.000136	0.00205	CcSEcCtD
Pravastatin—Vomiting—Cisplatin—bone cancer	0.000135	0.00204	CcSEcCtD
Pravastatin—Vision blurred—Methotrexate—bone cancer	0.000135	0.00203	CcSEcCtD
Pravastatin—Erythema multiforme—Doxorubicin—bone cancer	0.000135	0.00203	CcSEcCtD
Pravastatin—Rash—Cisplatin—bone cancer	0.000134	0.00202	CcSEcCtD
Pravastatin—Dermatitis—Cisplatin—bone cancer	0.000134	0.00202	CcSEcCtD
Pravastatin—Ill-defined disorder—Methotrexate—bone cancer	0.000133	0.002	CcSEcCtD
Pravastatin—Tinnitus—Doxorubicin—bone cancer	0.000133	0.002	CcSEcCtD
Pravastatin—Anaemia—Methotrexate—bone cancer	0.000132	0.00199	CcSEcCtD
Pravastatin—Cardiac disorder—Doxorubicin—bone cancer	0.000132	0.00199	CcSEcCtD
Pravastatin—Flushing—Doxorubicin—bone cancer	0.000132	0.00199	CcSEcCtD
Pravastatin—Flatulence—Epirubicin—bone cancer	0.000132	0.00199	CcSEcCtD
Pravastatin—Tension—Epirubicin—bone cancer	0.000132	0.00198	CcSEcCtD
Pravastatin—Dysgeusia—Epirubicin—bone cancer	0.000131	0.00198	CcSEcCtD
Pravastatin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00013	0.00304	CbGpPWpGaD
Pravastatin—Nervousness—Epirubicin—bone cancer	0.00013	0.00196	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00013	0.00304	CbGpPWpGaD
Pravastatin—SLC22A11—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000129	0.00301	CbGpPWpGaD
Pravastatin—Malaise—Methotrexate—bone cancer	0.000129	0.00194	CcSEcCtD
Pravastatin—Muscle spasms—Epirubicin—bone cancer	0.000129	0.00194	CcSEcCtD
Pravastatin—Vertigo—Methotrexate—bone cancer	0.000129	0.00194	CcSEcCtD
Pravastatin—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000129	0.003	CbGpPWpGaD
Pravastatin—Leukopenia—Methotrexate—bone cancer	0.000128	0.00193	CcSEcCtD
Pravastatin—Chills—Doxorubicin—bone cancer	0.000128	0.00192	CcSEcCtD
Pravastatin—Arrhythmia—Doxorubicin—bone cancer	0.000127	0.00192	CcSEcCtD
Pravastatin—SLC16A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000127	0.00296	CbGpPWpGaD
Pravastatin—Nausea—Cisplatin—bone cancer	0.000127	0.00191	CcSEcCtD
Pravastatin—Vision blurred—Epirubicin—bone cancer	0.000126	0.0019	CcSEcCtD
Pravastatin—Alopecia—Doxorubicin—bone cancer	0.000126	0.0019	CcSEcCtD
Pravastatin—Cough—Methotrexate—bone cancer	0.000125	0.00188	CcSEcCtD
Pravastatin—Ill-defined disorder—Epirubicin—bone cancer	0.000124	0.00187	CcSEcCtD
Pravastatin—Anaemia—Epirubicin—bone cancer	0.000124	0.00187	CcSEcCtD
Pravastatin—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000123	0.00287	CbGpPWpGaD
Pravastatin—Flatulence—Doxorubicin—bone cancer	0.000122	0.00184	CcSEcCtD
Pravastatin—Myalgia—Methotrexate—bone cancer	0.000122	0.00184	CcSEcCtD
Pravastatin—Chest pain—Methotrexate—bone cancer	0.000122	0.00184	CcSEcCtD
Pravastatin—Arthralgia—Methotrexate—bone cancer	0.000122	0.00184	CcSEcCtD
Pravastatin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000122	0.00284	CbGpPWpGaD
Pravastatin—Tension—Doxorubicin—bone cancer	0.000122	0.00183	CcSEcCtD
Pravastatin—Dysgeusia—Doxorubicin—bone cancer	0.000121	0.00183	CcSEcCtD
Pravastatin—Malaise—Epirubicin—bone cancer	0.000121	0.00182	CcSEcCtD
Pravastatin—Discomfort—Methotrexate—bone cancer	0.00012	0.00181	CcSEcCtD
Pravastatin—Nervousness—Doxorubicin—bone cancer	0.00012	0.00181	CcSEcCtD
Pravastatin—Vertigo—Epirubicin—bone cancer	0.00012	0.00181	CcSEcCtD
Pravastatin—Leukopenia—Epirubicin—bone cancer	0.00012	0.00181	CcSEcCtD
Pravastatin—Muscle spasms—Doxorubicin—bone cancer	0.000119	0.0018	CcSEcCtD
Pravastatin—Confusional state—Methotrexate—bone cancer	0.000118	0.00177	CcSEcCtD
Pravastatin—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000117	0.00274	CbGpPWpGaD
Pravastatin—Cough—Epirubicin—bone cancer	0.000117	0.00176	CcSEcCtD
Pravastatin—Anaphylactic shock—Methotrexate—bone cancer	0.000117	0.00176	CcSEcCtD
Pravastatin—Vision blurred—Doxorubicin—bone cancer	0.000117	0.00176	CcSEcCtD
Pravastatin—Infection—Methotrexate—bone cancer	0.000116	0.00175	CcSEcCtD
Pravastatin—Hypertension—Epirubicin—bone cancer	0.000116	0.00174	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000115	0.00269	CbGpPWpGaD
Pravastatin—Ill-defined disorder—Doxorubicin—bone cancer	0.000115	0.00173	CcSEcCtD
Pravastatin—Anaemia—Doxorubicin—bone cancer	0.000115	0.00173	CcSEcCtD
Pravastatin—Thrombocytopenia—Methotrexate—bone cancer	0.000114	0.00172	CcSEcCtD
Pravastatin—Chest pain—Epirubicin—bone cancer	0.000114	0.00172	CcSEcCtD
Pravastatin—Arthralgia—Epirubicin—bone cancer	0.000114	0.00172	CcSEcCtD
Pravastatin—Myalgia—Epirubicin—bone cancer	0.000114	0.00172	CcSEcCtD
Pravastatin—Anxiety—Epirubicin—bone cancer	0.000114	0.00171	CcSEcCtD
Pravastatin—HMGCR—Metabolism—NDUFA12—bone cancer	0.000113	0.00264	CbGpPWpGaD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000113	0.00264	CbGpPWpGaD
Pravastatin—Hyperhidrosis—Methotrexate—bone cancer	0.000113	0.0017	CcSEcCtD
Pravastatin—Discomfort—Epirubicin—bone cancer	0.000113	0.0017	CcSEcCtD
Pravastatin—Malaise—Doxorubicin—bone cancer	0.000112	0.00168	CcSEcCtD
Pravastatin—SLC22A11—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000112	0.0026	CbGpPWpGaD
Pravastatin—Vertigo—Doxorubicin—bone cancer	0.000111	0.00168	CcSEcCtD
Pravastatin—Anorexia—Methotrexate—bone cancer	0.000111	0.00168	CcSEcCtD
Pravastatin—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000111	0.0026	CbGpPWpGaD
Pravastatin—Leukopenia—Doxorubicin—bone cancer	0.000111	0.00167	CcSEcCtD
Pravastatin—Confusional state—Epirubicin—bone cancer	0.00011	0.00166	CcSEcCtD
Pravastatin—Anaphylactic shock—Epirubicin—bone cancer	0.000109	0.00165	CcSEcCtD
Pravastatin—Oedema—Epirubicin—bone cancer	0.000109	0.00165	CcSEcCtD
Pravastatin—SLC16A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000109	0.00255	CbGpPWpGaD
Pravastatin—Infection—Epirubicin—bone cancer	0.000109	0.00164	CcSEcCtD
Pravastatin—Cough—Doxorubicin—bone cancer	0.000108	0.00163	CcSEcCtD
Pravastatin—Thrombocytopenia—Epirubicin—bone cancer	0.000107	0.00161	CcSEcCtD
Pravastatin—Hypertension—Doxorubicin—bone cancer	0.000107	0.00161	CcSEcCtD
Pravastatin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000107	0.00249	CbGpPWpGaD
Pravastatin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000107	0.0016	CcSEcCtD
Pravastatin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000106	0.00247	CbGpPWpGaD
Pravastatin—Hyperhidrosis—Epirubicin—bone cancer	0.000106	0.00159	CcSEcCtD
Pravastatin—Insomnia—Methotrexate—bone cancer	0.000106	0.00159	CcSEcCtD
Pravastatin—Arthralgia—Doxorubicin—bone cancer	0.000106	0.00159	CcSEcCtD
Pravastatin—Myalgia—Doxorubicin—bone cancer	0.000106	0.00159	CcSEcCtD
Pravastatin—Chest pain—Doxorubicin—bone cancer	0.000106	0.00159	CcSEcCtD
Pravastatin—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000106	0.00246	CbGpPWpGaD
Pravastatin—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000106	0.00246	CbGpPWpGaD
Pravastatin—Anxiety—Doxorubicin—bone cancer	0.000105	0.00158	CcSEcCtD
Pravastatin—Paraesthesia—Methotrexate—bone cancer	0.000105	0.00158	CcSEcCtD
Pravastatin—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000105	0.00244	CbGpPWpGaD
Pravastatin—Discomfort—Doxorubicin—bone cancer	0.000104	0.00157	CcSEcCtD
Pravastatin—Anorexia—Epirubicin—bone cancer	0.000104	0.00157	CcSEcCtD
Pravastatin—Dyspnoea—Methotrexate—bone cancer	0.000104	0.00157	CcSEcCtD
Pravastatin—HMGCR—AMPK Signaling—TP53—bone cancer	0.000104	0.00242	CbGpPWpGaD
Pravastatin—Dyspepsia—Methotrexate—bone cancer	0.000103	0.00155	CcSEcCtD
Pravastatin—Confusional state—Doxorubicin—bone cancer	0.000102	0.00154	CcSEcCtD
Pravastatin—Decreased appetite—Methotrexate—bone cancer	0.000102	0.00153	CcSEcCtD
Pravastatin—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000101	0.00236	CbGpPWpGaD
Pravastatin—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000101	0.00236	CbGpPWpGaD
Pravastatin—Anaphylactic shock—Doxorubicin—bone cancer	0.000101	0.00152	CcSEcCtD
Pravastatin—Oedema—Doxorubicin—bone cancer	0.000101	0.00152	CcSEcCtD
Pravastatin—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000101	0.00236	CbGpPWpGaD
Pravastatin—Fatigue—Methotrexate—bone cancer	0.000101	0.00152	CcSEcCtD
Pravastatin—Infection—Doxorubicin—bone cancer	0.000101	0.00151	CcSEcCtD
Pravastatin—Pain—Methotrexate—bone cancer	0.0001	0.00151	CcSEcCtD
Pravastatin—Musculoskeletal discomfort—Epirubicin—bone cancer	9.97e-05	0.0015	CcSEcCtD
Pravastatin—Thrombocytopenia—Doxorubicin—bone cancer	9.91e-05	0.00149	CcSEcCtD
Pravastatin—SLC16A1—Metabolism—NDUFA12—bone cancer	9.91e-05	0.00231	CbGpPWpGaD
Pravastatin—Insomnia—Epirubicin—bone cancer	9.9e-05	0.00149	CcSEcCtD
Pravastatin—SLC22A8—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.86e-05	0.0023	CbGpPWpGaD
Pravastatin—Paraesthesia—Epirubicin—bone cancer	9.82e-05	0.00148	CcSEcCtD
Pravastatin—Hyperhidrosis—Doxorubicin—bone cancer	9.79e-05	0.00147	CcSEcCtD
Pravastatin—Dyspnoea—Epirubicin—bone cancer	9.75e-05	0.00147	CcSEcCtD
Pravastatin—Anorexia—Doxorubicin—bone cancer	9.65e-05	0.00145	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—MDM2—bone cancer	9.65e-05	0.00225	CbGpPWpGaD
Pravastatin—Feeling abnormal—Methotrexate—bone cancer	9.63e-05	0.00145	CcSEcCtD
Pravastatin—Dyspepsia—Epirubicin—bone cancer	9.63e-05	0.00145	CcSEcCtD
Pravastatin—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.61e-05	0.00224	CbGpPWpGaD
Pravastatin—Gastrointestinal pain—Methotrexate—bone cancer	9.56e-05	0.00144	CcSEcCtD
Pravastatin—Decreased appetite—Epirubicin—bone cancer	9.51e-05	0.00143	CcSEcCtD
Pravastatin—Fatigue—Epirubicin—bone cancer	9.43e-05	0.00142	CcSEcCtD
Pravastatin—HMGCR—Metabolism—NT5C3A—bone cancer	9.39e-05	0.00219	CbGpPWpGaD
Pravastatin—Pain—Epirubicin—bone cancer	9.36e-05	0.00141	CcSEcCtD
Pravastatin—Constipation—Epirubicin—bone cancer	9.36e-05	0.00141	CcSEcCtD
Pravastatin—Urticaria—Methotrexate—bone cancer	9.29e-05	0.0014	CcSEcCtD
Pravastatin—Abdominal pain—Methotrexate—bone cancer	9.24e-05	0.00139	CcSEcCtD
Pravastatin—Body temperature increased—Methotrexate—bone cancer	9.24e-05	0.00139	CcSEcCtD
Pravastatin—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.22e-05	0.00139	CcSEcCtD
Pravastatin—Insomnia—Doxorubicin—bone cancer	9.16e-05	0.00138	CcSEcCtD
Pravastatin—Paraesthesia—Doxorubicin—bone cancer	9.09e-05	0.00137	CcSEcCtD
Pravastatin—Dyspnoea—Doxorubicin—bone cancer	9.03e-05	0.00136	CcSEcCtD
Pravastatin—Feeling abnormal—Epirubicin—bone cancer	9.02e-05	0.00136	CcSEcCtD
Pravastatin—Gastrointestinal pain—Epirubicin—bone cancer	8.95e-05	0.00135	CcSEcCtD
Pravastatin—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	8.93e-05	0.00208	CbGpPWpGaD
Pravastatin—Dyspepsia—Doxorubicin—bone cancer	8.91e-05	0.00134	CcSEcCtD
Pravastatin—Decreased appetite—Doxorubicin—bone cancer	8.8e-05	0.00132	CcSEcCtD
Pravastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.75e-05	0.00204	CbGpPWpGaD
Pravastatin—Fatigue—Doxorubicin—bone cancer	8.73e-05	0.00131	CcSEcCtD
Pravastatin—SLCO1B3—Metabolism—NDUFA12—bone cancer	8.71e-05	0.00203	CbGpPWpGaD
Pravastatin—Urticaria—Epirubicin—bone cancer	8.69e-05	0.00131	CcSEcCtD
Pravastatin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.67e-05	0.00202	CbGpPWpGaD
Pravastatin—Pain—Doxorubicin—bone cancer	8.66e-05	0.0013	CcSEcCtD
Pravastatin—Constipation—Doxorubicin—bone cancer	8.66e-05	0.0013	CcSEcCtD
Pravastatin—Body temperature increased—Epirubicin—bone cancer	8.65e-05	0.0013	CcSEcCtD
Pravastatin—Abdominal pain—Epirubicin—bone cancer	8.65e-05	0.0013	CcSEcCtD
Pravastatin—Hypersensitivity—Methotrexate—bone cancer	8.61e-05	0.0013	CcSEcCtD
Pravastatin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.59e-05	0.002	CbGpPWpGaD
Pravastatin—SLC22A8—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.51e-05	0.00198	CbGpPWpGaD
Pravastatin—SLC16A1—Hemostasis—SPARC—bone cancer	8.41e-05	0.00196	CbGpPWpGaD
Pravastatin—Asthenia—Methotrexate—bone cancer	8.39e-05	0.00126	CcSEcCtD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—bone cancer	8.38e-05	0.00196	CbGpPWpGaD
Pravastatin—Feeling abnormal—Doxorubicin—bone cancer	8.34e-05	0.00126	CcSEcCtD
Pravastatin—Gastrointestinal pain—Doxorubicin—bone cancer	8.28e-05	0.00125	CcSEcCtD
Pravastatin—Pruritus—Methotrexate—bone cancer	8.27e-05	0.00125	CcSEcCtD
Pravastatin—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.23e-05	0.00192	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—NT5C3A—bone cancer	8.21e-05	0.00192	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—NDUFA12—bone cancer	8.2e-05	0.00191	CbGpPWpGaD
Pravastatin—Hypersensitivity—Epirubicin—bone cancer	8.06e-05	0.00121	CcSEcCtD
Pravastatin—Urticaria—Doxorubicin—bone cancer	8.04e-05	0.00121	CcSEcCtD
Pravastatin—Body temperature increased—Doxorubicin—bone cancer	8e-05	0.0012	CcSEcCtD
Pravastatin—Abdominal pain—Doxorubicin—bone cancer	8e-05	0.0012	CcSEcCtD
Pravastatin—Diarrhoea—Methotrexate—bone cancer	8e-05	0.0012	CcSEcCtD
Pravastatin—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.97e-05	0.00186	CbGpPWpGaD
Pravastatin—Asthenia—Epirubicin—bone cancer	7.85e-05	0.00118	CcSEcCtD
Pravastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	7.79e-05	0.00182	CbGpPWpGaD
Pravastatin—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	7.77e-05	0.00181	CbGpPWpGaD
Pravastatin—Pruritus—Epirubicin—bone cancer	7.74e-05	0.00117	CcSEcCtD
Pravastatin—Dizziness—Methotrexate—bone cancer	7.73e-05	0.00116	CcSEcCtD
Pravastatin—SLC16A1—Hemostasis—GNA11—bone cancer	7.69e-05	0.00179	CbGpPWpGaD
Pravastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.55e-05	0.00176	CbGpPWpGaD
Pravastatin—Diarrhoea—Epirubicin—bone cancer	7.49e-05	0.00113	CcSEcCtD
Pravastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.48e-05	0.00175	CbGpPWpGaD
Pravastatin—Hypersensitivity—Doxorubicin—bone cancer	7.46e-05	0.00112	CcSEcCtD
Pravastatin—Vomiting—Methotrexate—bone cancer	7.43e-05	0.00112	CcSEcCtD
Pravastatin—Rash—Methotrexate—bone cancer	7.37e-05	0.00111	CcSEcCtD
Pravastatin—Dermatitis—Methotrexate—bone cancer	7.36e-05	0.00111	CcSEcCtD
Pravastatin—Headache—Methotrexate—bone cancer	7.32e-05	0.0011	CcSEcCtD
Pravastatin—Asthenia—Doxorubicin—bone cancer	7.26e-05	0.00109	CcSEcCtD
Pravastatin—Dizziness—Epirubicin—bone cancer	7.24e-05	0.00109	CcSEcCtD
Pravastatin—SLCO1B3—Metabolism—NT5C3A—bone cancer	7.22e-05	0.00168	CbGpPWpGaD
Pravastatin—Pruritus—Doxorubicin—bone cancer	7.16e-05	0.00108	CcSEcCtD
Pravastatin—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.1e-05	0.00166	CbGpPWpGaD
Pravastatin—SLC16A1—Hemostasis—IL3—bone cancer	6.97e-05	0.00163	CbGpPWpGaD
Pravastatin—Vomiting—Epirubicin—bone cancer	6.96e-05	0.00105	CcSEcCtD
Pravastatin—Nausea—Methotrexate—bone cancer	6.94e-05	0.00105	CcSEcCtD
Pravastatin—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.93e-05	0.00162	CbGpPWpGaD
Pravastatin—Diarrhoea—Doxorubicin—bone cancer	6.93e-05	0.00104	CcSEcCtD
Pravastatin—Rash—Epirubicin—bone cancer	6.9e-05	0.00104	CcSEcCtD
Pravastatin—Dermatitis—Epirubicin—bone cancer	6.89e-05	0.00104	CcSEcCtD
Pravastatin—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.88e-05	0.0016	CbGpPWpGaD
Pravastatin—Headache—Epirubicin—bone cancer	6.85e-05	0.00103	CcSEcCtD
Pravastatin—SLCO1A2—Metabolism—NDUFA12—bone cancer	6.84e-05	0.0016	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—NT5C3A—bone cancer	6.79e-05	0.00158	CbGpPWpGaD
Pravastatin—Dizziness—Doxorubicin—bone cancer	6.69e-05	0.00101	CcSEcCtD
Pravastatin—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	6.68e-05	0.00156	CbGpPWpGaD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—EGFR—bone cancer	6.59e-05	0.00154	CbGpPWpGaD
Pravastatin—Nausea—Epirubicin—bone cancer	6.5e-05	0.000978	CcSEcCtD
Pravastatin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	6.48e-05	0.00151	CbGpPWpGaD
Pravastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.46e-05	0.00151	CbGpPWpGaD
Pravastatin—Vomiting—Doxorubicin—bone cancer	6.44e-05	0.000969	CcSEcCtD
Pravastatin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	6.39e-05	0.00149	CbGpPWpGaD
Pravastatin—Rash—Doxorubicin—bone cancer	6.38e-05	0.000961	CcSEcCtD
Pravastatin—Dermatitis—Doxorubicin—bone cancer	6.38e-05	0.00096	CcSEcCtD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.37e-05	0.00149	CbGpPWpGaD
Pravastatin—Headache—Doxorubicin—bone cancer	6.34e-05	0.000955	CcSEcCtD
Pravastatin—Nausea—Doxorubicin—bone cancer	6.01e-05	0.000905	CcSEcCtD
Pravastatin—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.98e-05	0.0014	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—NDUFA12—bone cancer	5.85e-05	0.00136	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—NT5C3A—bone cancer	5.67e-05	0.00132	CbGpPWpGaD
Pravastatin—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.61e-05	0.00131	CbGpPWpGaD
Pravastatin—CYP3A5—Biological oxidations—GSTP1—bone cancer	5.54e-05	0.00129	CbGpPWpGaD
Pravastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—bone cancer	5.53e-05	0.00129	CbGpPWpGaD
Pravastatin—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.53e-05	0.00129	CbGpPWpGaD
Pravastatin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	5.46e-05	0.00127	CbGpPWpGaD
Pravastatin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.43e-05	0.00127	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.42e-05	0.00126	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—NDUFA12—bone cancer	5.42e-05	0.00126	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.93e-05	0.00115	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—NT5C3A—bone cancer	4.85e-05	0.00113	CbGpPWpGaD
Pravastatin—CYP2C8—Biological oxidations—GSTP1—bone cancer	4.8e-05	0.00112	CbGpPWpGaD
Pravastatin—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	4.73e-05	0.0011	CbGpPWpGaD
Pravastatin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	4.6e-05	0.00107	CbGpPWpGaD
Pravastatin—SLC16A1—Hemostasis—PLAU—bone cancer	4.57e-05	0.00107	CbGpPWpGaD
Pravastatin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.56e-05	0.00106	CbGpPWpGaD
Pravastatin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	4.54e-05	0.00106	CbGpPWpGaD
Pravastatin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.5e-05	0.00105	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.49e-05	0.00105	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—NT5C3A—bone cancer	4.49e-05	0.00105	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.43e-05	0.00103	CbGpPWpGaD
Pravastatin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.2e-05	0.00098	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—ENO2—bone cancer	4.11e-05	0.00096	CbGpPWpGaD
Pravastatin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.97e-05	0.000927	CbGpPWpGaD
Pravastatin—CYP2D6—Biological oxidations—GSTP1—bone cancer	3.94e-05	0.000919	CbGpPWpGaD
Pravastatin—CYP2C9—Biological oxidations—GSTP1—bone cancer	3.9e-05	0.000911	CbGpPWpGaD
Pravastatin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	3.88e-05	0.000906	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—NDUFA12—bone cancer	3.88e-05	0.000905	CbGpPWpGaD
Pravastatin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.85e-05	0.000898	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—DHFR—bone cancer	3.82e-05	0.00089	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.76e-05	0.000876	CbGpPWpGaD
Pravastatin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.75e-05	0.000874	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—ENO2—bone cancer	3.6e-05	0.000839	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—GNA11—bone cancer	3.57e-05	0.000832	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—NDUFA12—bone cancer	3.36e-05	0.000784	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—DHFR—bone cancer	3.34e-05	0.000778	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—CYP3A4—bone cancer	3.23e-05	0.000754	CbGpPWpGaD
Pravastatin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.23e-05	0.000754	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.22e-05	0.000751	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—NT5C3A—bone cancer	3.22e-05	0.00075	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—ENO2—bone cancer	3.16e-05	0.000737	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—GNA11—bone cancer	3.12e-05	0.000727	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—ENO2—bone cancer	2.97e-05	0.000694	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—DHFR—bone cancer	2.93e-05	0.000684	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—NDUFA12—bone cancer	2.93e-05	0.000683	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—CYP3A4—bone cancer	2.83e-05	0.000659	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.79e-05	0.00065	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—NT5C3A—bone cancer	2.79e-05	0.00065	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—GSTP1—bone cancer	2.77e-05	0.000645	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—NDUFA12—bone cancer	2.76e-05	0.000644	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—DHFR—bone cancer	2.76e-05	0.000644	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—GNA11—bone cancer	2.74e-05	0.000639	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—NDUFA12—bone cancer	2.74e-05	0.000638	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—GNA11—bone cancer	2.58e-05	0.000602	CbGpPWpGaD
Pravastatin—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.57e-05	0.000601	CbGpPWpGaD
Pravastatin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.54e-05	0.000592	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—CYP3A4—bone cancer	2.48e-05	0.00058	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—ENO2—bone cancer	2.48e-05	0.000579	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.47e-05	0.000577	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—NT5C3A—bone cancer	2.43e-05	0.000566	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—GSTP1—bone cancer	2.42e-05	0.000564	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—CYP3A4—bone cancer	2.34e-05	0.000545	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.33e-05	0.000543	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—DHFR—bone cancer	2.3e-05	0.000537	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—NT5C3A—bone cancer	2.29e-05	0.000533	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—NT5C3A—bone cancer	2.27e-05	0.000529	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—GNA11—bone cancer	2.15e-05	0.000502	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—GSTP1—bone cancer	2.12e-05	0.000496	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—ENO2—bone cancer	2.12e-05	0.000495	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.07e-05	0.000482	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—GSTP1—bone cancer	2e-05	0.000466	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.99e-05	0.000464	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—DHFR—bone cancer	1.97e-05	0.00046	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—ENO2—bone cancer	1.97e-05	0.000459	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—CYP3A4—bone cancer	1.95e-05	0.000455	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.94e-05	0.000453	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—GNA11—bone cancer	1.84e-05	0.000429	CbGpPWpGaD
Pravastatin—SLC16A1—Hemostasis—TP53—bone cancer	1.84e-05	0.000429	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—DHFR—bone cancer	1.82e-05	0.000426	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—NDUFA12—bone cancer	1.8e-05	0.000421	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.8e-05	0.000419	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—GNA11—bone cancer	1.7e-05	0.000398	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—GSTP1—bone cancer	1.67e-05	0.000389	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.67e-05	0.000389	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.66e-05	0.000387	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—CYP3A4—bone cancer	1.55e-05	0.000361	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—NT5C3A—bone cancer	1.5e-05	0.000349	CbGpPWpGaD
Pravastatin—HMGCR—Metabolism—PTGS2—bone cancer	1.43e-05	0.000334	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—GSTP1—bone cancer	1.43e-05	0.000333	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.41e-05	0.000329	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—ENO2—bone cancer	1.41e-05	0.000329	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—GSTP1—bone cancer	1.32e-05	0.000308	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—DHFR—bone cancer	1.31e-05	0.000305	CbGpPWpGaD
Pravastatin—SLC16A1—Metabolism—PTGS2—bone cancer	1.25e-05	0.000292	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—GNA11—bone cancer	1.22e-05	0.000285	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—ENO2—bone cancer	1.22e-05	0.000285	CbGpPWpGaD
Pravastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.19e-05	0.000276	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—DHFR—bone cancer	1.13e-05	0.000264	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000258	CbGpPWpGaD
Pravastatin—SLCO1B3—Metabolism—PTGS2—bone cancer	1.1e-05	0.000257	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—ENO2—bone cancer	1.06e-05	0.000248	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—GNA11—bone cancer	1.06e-05	0.000247	CbGpPWpGaD
Pravastatin—ABCB11—Metabolism—PTGS2—bone cancer	1.04e-05	0.000242	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—ENO2—bone cancer	1e-05	0.000234	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—ENO2—bone cancer	9.93e-06	0.000232	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—DHFR—bone cancer	9.86e-06	0.00023	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—CYP3A4—bone cancer	9.59e-06	0.000224	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.54e-06	0.000223	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—GSTP1—bone cancer	9.47e-06	0.000221	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—DHFR—bone cancer	9.29e-06	0.000217	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—GNA11—bone cancer	9.22e-06	0.000215	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—DHFR—bone cancer	9.21e-06	0.000215	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—GNA11—bone cancer	8.69e-06	0.000203	CbGpPWpGaD
Pravastatin—SLCO1A2—Metabolism—PTGS2—bone cancer	8.65e-06	0.000202	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—GNA11—bone cancer	8.61e-06	0.000201	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—CYP3A4—bone cancer	8.36e-06	0.000195	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—GSTP1—bone cancer	8.2e-06	0.000191	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—CYP3A4—bone cancer	7.87e-06	0.000184	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—CYP3A4—bone cancer	7.81e-06	0.000182	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.77e-06	0.000181	CbGpPWpGaD
Pravastatin—SLCO1B1—Metabolism—PTGS2—bone cancer	7.4e-06	0.000173	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—GSTP1—bone cancer	7.15e-06	0.000167	CbGpPWpGaD
Pravastatin—ABCG2—Metabolism—PTGS2—bone cancer	6.85e-06	0.00016	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—GSTP1—bone cancer	6.74e-06	0.000157	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—GSTP1—bone cancer	6.68e-06	0.000156	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—ENO2—bone cancer	6.55e-06	0.000153	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—DHFR—bone cancer	6.08e-06	0.000142	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—GNA11—bone cancer	5.68e-06	0.000132	CbGpPWpGaD
Pravastatin—CYP3A5—Metabolism—PTGS2—bone cancer	4.91e-06	0.000114	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—GSTP1—bone cancer	4.4e-06	0.000103	CbGpPWpGaD
Pravastatin—CYP2C8—Metabolism—PTGS2—bone cancer	4.25e-06	9.91e-05	CbGpPWpGaD
Pravastatin—ABCB1—Metabolism—PTGS2—bone cancer	3.7e-06	8.64e-05	CbGpPWpGaD
Pravastatin—CYP2D6—Metabolism—PTGS2—bone cancer	3.49e-06	8.14e-05	CbGpPWpGaD
Pravastatin—CYP2C9—Metabolism—PTGS2—bone cancer	3.46e-06	8.07e-05	CbGpPWpGaD
Pravastatin—CYP3A4—Metabolism—PTGS2—bone cancer	2.28e-06	5.32e-05	CbGpPWpGaD
